Shares of Humacyte, Inc. (HUMA) soared 5.51% in pre-market trading on Wednesday, despite the biotechnology company reporting a wider net loss for the third quarter of 2024 compared to analysts' expectations.
Humacyte posted an operating loss of $30.23 million for Q3 2024, slightly higher than the consensus estimate of $29.7 million. The net loss for the quarter came in at $39.2 million or $0.33 per share, compared to Wall Street's expectations of a $30 million loss.
Despite the headline numbers missing estimates, investors appeared to be focusing on other factors, driving Humacyte's stock higher ahead of the market open. The company did not provide additional commentary in its earnings release to explain the pre-market surge, leaving investors to speculate on the reasons behind the positive stock movement.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。